Patterns and predictors of opioid use among migraine patients at emergency departments: A retrospective database analysis

Objectives To compare medication use and health resource utilization between migraineurs with evidence of opioid use at emergency department visit versus no opioid use at emergency department visit, and to examine predictors of opioid use among migraineurs at emergency department visits. Methods This was a retrospective study using REACHnet electronic health records (December 2013 to April 2017) from Baylor Scott & White Health Plan. The index date was defined as the first migraine-related emergency department visit after ≥6 months of enrollment. Adult patients with a migraine diagnosis and ≥6 months of continuous enrollment before and after their index dates were included. Descriptive statistics and bivariate analyses were used to compare medication use and health resource utilization between opioid users and non-opioid users. Multivariable logistic regression was used to examine predictors of opioid use at emergency department visits. Results A total of 788 migraineurs met eligibility criteria. Over one-third (n = 283, 35.9%) received ≥1 opioid medication during their index date emergency department visit. Morphine (n = 103, 13.1%) and hydromorphone (n = 85, 10.8%) were the most frequently used opioids. Opioid users had more hospitalizations and emergency department visits during their pre-index period (both p < 0.05). Significant (p < 0.05) predictors of opioid use at emergency department visits included past migraine-related opioid use (2–4 prescriptions, Odds Ratio = 1.66; 5–9 prescriptions, Odds Ratio = 2.12; ≥10 prescriptions, Odds Ratio = 4.43), past non-migraine-related opioid use (≥10 prescriptions, Odds Ratio = 1.93), past emergency department visits (1–3 visits, Odds Ratio = 1.84), age (45–64 years, Odds Ratio = 1.45), and sleep disorder (Odds Ratio = 1.43), controlling for covariates. Conclusion Opioids were commonly given to migraineurs at emergency departments. Previous opioid use, health resource utilization, age, and specific comorbidities might be used to identify migraineurs with a high risk of opioid use.

[1]  M. Shibata,et al.  [Medication-overuse headache]. , 2020, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[2]  Ivy Shiue,et al.  Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[3]  S. Joukar,et al.  Opioids and Cardiac Arrhythmia: A Literature Review , 2018, Medical Principles and Practice.

[4]  J. Pavlović,et al.  Sleep Disorders and Migraine: Review of Literature and Potential Pathophysiology Mechanisms , 2018, Headache.

[5]  M. Bonafede,et al.  Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States , 2018, Headache.

[6]  E. Loder,et al.  The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies , 2018, Headache.

[7]  J. Finkelstein,et al.  Multicenter prevalence of opioid medication use as abortive therapy in the ED treatment of migraine headaches , 2017, The American journal of emergency medicine.

[8]  Craig M. Hales,et al.  Hypertension Prevalence and Control Among Adults: United States, 2015-2016. , 2017, NCHS data brief.

[9]  Heidi Moawad Migraine and Depression: Is There a Link? , 2017 .

[10]  Nancy E. Kelley,et al.  Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies , 2016, Headache.

[11]  D. Boomsma,et al.  Genetic epidemiology of migraine and depression , 2016, Cephalalgia : an international journal of headache.

[12]  M. Carroll,et al.  Hypertension Prevalence and Control Among Adults: United States, 2011-2014. , 2015, NCHS data brief.

[13]  L. Webster,et al.  Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies. , 2015, Pain medicine.

[14]  E. Gallagher,et al.  Current management of migraine in US emergency departments: An analysis of the National Hospital Ambulatory Medical Care Survey* , 2015, Cephalalgia : an international journal of headache.

[15]  S. Silberstein,et al.  The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies , 2015, Headache.

[16]  D. Turk,et al.  Associations between prescription opioid use and sleep impairment among veterans with chronic pain. , 2014, Pain medicine.

[17]  R. Lipton,et al.  Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study , 2012, Headache.

[18]  S. Silberstein,et al.  Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults , 2012, Neurology.

[19]  S. Pearlman,et al.  Opioid Use and Dependence Among Persons With Migraine: Results of the AMPP Study , 2012, Headache.

[20]  A. Elixhauser,et al.  Headaches in U.S. Hospitals and Emergency Departments, 2008 , 2011 .

[21]  R. Lipton,et al.  Patterns of medication use by chronic and episodic headache sufferers in the general population: Results from the frequent headache epidemiology study , 2010, Cephalalgia : an international journal of headache.

[22]  R. Lipton,et al.  Use of the Emergency Department for Severe Headache. A Population‐Based Study , 2009, Headache.

[23]  W. Stewart,et al.  Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population‐Based Study , 2008, Headache.

[24]  J. -. Park,et al.  Decreased number and function of endothelial progenitor cells in patients with migraine , 2008, Neurology.

[25]  R. Lipton,et al.  Migraine prevalence, disease burden, and the need for preventive therapy , 2007, Neurology.

[26]  R. Gilder,et al.  A Comparison of a Fentanyl, Morphine, and Hydromorphone Patient-Controlled Intravenous Delivery for Acute Postoperative Analgesia: A Multicenter Study of Opioid-Induced Adverse Reactions , 2006 .

[27]  R. Lipton,et al.  Migraine: Epidemiology, Impact, and Risk Factors for Progression , 2005, Headache.

[28]  Jes Olesen,et al.  The International Classification of Headache Disorders: 2nd edition. , 2004, Cephalalgia : an international journal of headache.

[29]  B. Rasmussen Epidemiology of Headache , 2001, Cephalalgia : an international journal of headache.

[30]  R. Lipton,et al.  Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II , 2001, Headache.

[31]  K. Lunetta,et al.  Implications of comorbidity and ascertainment bias for identifying disease genes. , 2000, American journal of medical genetics.

[32]  B. Akpunonu,et al.  Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. , 1995, Annals of emergency medicine.

[33]  W. Stewart,et al.  Population variation in migraine prevalence: a meta-analysis. , 1995, Journal of clinical epidemiology.

[34]  M. Arnold Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.

[35]  S. Pulfrey,et al.  Treatment of acute migraine in the emergency department. , 2014, Canadian family physician Medecin de famille canadien.

[36]  W F Stewart,et al.  Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. , 1992, JAMA.